Search

Your search keyword '"Scott Gavura"' showing total 42 results

Search Constraints

Start Over You searched for: Author "Scott Gavura" Remove constraint Author: "Scott Gavura" Topic business.industry Remove constraint Topic: business.industry
42 results on '"Scott Gavura"'

Search Results

1. Impact of rarity on Canadian oncology health technology assessment and funding

2. Assessing the efficacy‐effectiveness gap for cancer therapies: A comparison of overall survival and toxicity between clinical trial and population‐based, real‐world data for contemporary parenteral cancer therapeutics

3. Are population‐based patient‐reported outcomes associated with overall survival in patients with advanced pancreatic cancer?

4. Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces

5. Clinician Perspectives of COVID-19-Related Cancer Drug Funding Measures in Ontario

6. Real-world Safety of Bevacizumab with First-line Combination Chemotherapy in Patients with Metastatic Colorectal Cancer: Population-based Retrospective Cohort Studies in Three Canadian Provinces

7. Evolving Best Practice for Take-Home Cancer Drugs

8. Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada

9. The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer

10. Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration

11. Impact of a novel prioritization framework on clinician-led oncology drug submissions

12. Better treatment at what cost? A study of myeloma spending

13. Improved survival in overweight and obese patients with aggressive B-cell lymphoma treated with rituximab-containing chemotherapy for curative intent

14. Alternative Medicine and the Ethics Of Commerce

15. Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based study

16. Association of hospital and physician case volumes with cardiac monitoring and cardiotoxicity during adjuvant trastuzumab treatment for breast cancer: a retrospective cohort study

17. International Variability in the Reimbursement of Cancer Drugs by Publically Funded Drug Programs

18. Are real-world patient-reported outcomes associated with survival in patients with advanced pancreatic cancer?

19. Impact of novel chronic lymphocytic leukemia drugs on public spending

20. Evolving best practice for take-home cancer drugs in Ontario

21. Assessing the difference in efficacy and effectiveness of cancer systemic treatment (tx): A comparison of clinical trial (CT) overall survival (OS) and toxicity data with population-based, real world (RW) OS data

22. Pharmacy 2.0

23. Chemotherapy choice in advanced pancreatic cancer: What patient and disease factors influence prescription patterns?

24. Comparative effectiveness and safety of the implementation of universal public funding of FOLFIRINOX (FFX) and gemcitabine (G) + nab-paclitaxel (GnP) in advanced pancreatic cancer (APC): A population-based study

25. Clinical trials in Ontario’s quality-based funding model

26. Outcomes of FOLFIRINOX (FFX) and gemcitabine+nab-paclitaxel (GnP) in initially unresectable locally advanced pancreatic cancer (uLAPC): A population-based study

27. The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study

28. Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis

30. Pharmacy 2.0: a scoping review of social media use in pharmacy

31. Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab

32. Ontario’s approach to tackling drug funding sustainability

33. Systemic treatment patterns in small bowel and appendiceal adenocarcinomas (SBA and AA): A population-based study

34. Automating a program for the evidence-based reimbursement of oncology drugs across a complex network: Benefits and challenges

35. Enhancing the delivery of take-home cancer therapies in Ontario

36. Long-term risk of heart failure associated with adjuvant trastuzumab in breast cancer patients

37. Utilization of adjuvant trastuzumab for T1a,b N0 HER2+ breast cancer in Ontario

38. Managing chemotherapy drug shortages in Ontario

39. Impact of physician and center case volume on the adequacy of cardiac monitoring during adjuvant trastuzumab in breast cancer

41. Global variations in reimbursement of new cancer therapeutics: Improving access through risk-sharing agreements

42. Trends in trastuzumab utilization in Ontario: A single payer system

Catalog

Books, media, physical & digital resources